Guest Speaker

Shafieeq Ladha, MD
Barrow Neurological Institute, AZ
Platform Trial Site Investigator
Barrow ALS Research Team
- ALS Clinical Team
- Clinical Research Unit
- ALS Scientists
- BNI CRO

Barrow Healey Platform Trial Team
- Nicole Turcotte
- Jessie Duncan
- Dianna Thiessen
- Arubah Ahmed
- Bill Jacobsen
- Shafeeq Ladha
Perpetual Adaptive Trial
Shared Placebo; Randomization Ratio 3:1
Open Label Extension (OLE) offered

- Screening
- Regimen Assignment: (n=160 for each regimen)
- Regimen A
- Regimen B
- Regimen C
- Regimen D
- 3:1 Randomization within each Regimen: (n=120 for active; n=40 for placebo)
- Regimen Assignment: in each Regimen
- Informed Consent
- Assign to Regimen
- Randomize within Regimen (active/placebo)
- Open Label Extension
- Up to 6 weeks
- 24 weeks (about 6 months)
Enrollment Updates (as of July 15, 2021)

• 651 individuals with ALS signed informed consent
• 504 individuals were assigned to a regimen
• 458 individuals were randomized within a regimen (active or placebo)
• 139 have entered the Open Label Extension (OLE)

• 124 individuals were randomized within Regimen A
• 143 individuals were randomized within Regimen B
• 141 individuals were randomized within Regimen C
• 50 individuals were randomized within Regimen D

Thank You
This breakthrough trial would not be possible without your partnership
How to Find a Center Near You

52 sites are actively enrolling

Contact Info of Participating Sites by State

https://www.massgeneral.org/neurology/als/research/platform-trial-sites
Patient Navigator

Catherine Small
Allison Bulat
Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

To see whether you might qualify, view the list of eligibility criteria online:
Send us webinar ideas!

- Biomarkers
- Biostatistics / Trial Design
- Get to know our sites

Upcoming Guest Speakers:
July 22nd - Richard Bedlack, MD, PhD, MS (Duke University, NC)
July 29th - James Berry, MD, MPH (Mass General Hospital, MA)
               Hristelina Ilieva, MD, PhD (Thomas Jefferson, PA)
Aug 12th - Michael Weiss, MD, FAAN (University of Washington, WA)
Aug 19th - Laura Foster, MD (University of Colorado, CO)
For More Updates

- **Weekly webinars**
  The idea of came from our Patient Advisory Committee: we are excited to be talking with you on a weekly basis and take any questions you might have

- **Find the schedule and registration links on our website**
  https://www.massgeneral.org/neurology/als/research/platform-trial-news/

**Previously: Drug mechanism of action and science webinars**

- **Feb 4  -** Clene/CNM-Au8  (view recording- https://bit.ly/3jB3WWt)